A new CFTR modulator treatment called Alyftrek has been approved for people with CF ages 6 and older who have CFTR mutations that are eligible for Trikafta, as well as 31 other rare mutations that ...
--(BUSINESS WIRE)--SiteOne Therapeutics, Inc., a biopharmaceutical company developing selective ion channel modulators for the treatment of pain, cough, and other conditions, today announced a $ ...
Warren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, ...